These highlights do not include all the information needed to use Fludeoxyglucose F18 Injection safely and effectively. See full prescribing information for Fludeoxyglucose F18 Injection. Fludeoxyglucose F18 InjectionInitial U.S. Approval: 2005 | Fludeoxyglucose F18 [Biomedical Research Foundation of Northwest Louisiana] | BioPortfolio

12:54 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Fludeoxyglucose F18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:

For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.

For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.

For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.

Fludeoxyglucose F18 Injection emits radiation. Use procedures to minimize radiation exposure. Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors. Assay the final dose in a properly calibrated dose calibrator before administration to the patient [see Description(11.2)].

Within the oncology, cardiology and neurology settings, the recommended dose for adults is 5 – 10 mCi (185 – 370 MBq) as an intravenous injection.

Within the neurology setting, the recommended dose for pediatric patients is 2.6 mCi, as an intravenous injection. The optimal dose adjustment on the basis of body size or weight has not been determined [see Use in Special Populations(8.4)].

The estimated human absorbed radiation doses (rem/mCi) to a newborn (3.4 kg), 1-year old (9.8 kg), 5-year old (19 kg), 10-year old (32 kg), 15-year old (57 kg), and adult (70 kg) from intravenous administration of Fludeoxyglucose F18 Injection are shown in Table 1. These estimates were calculated based on human2 data and using the data published by the International Commission on Radiological Protection4 for Fludeoxyglucose 18F. The dosimetry data show that there are slight variations in absorbed radiation dose for various organs in each of the age groups. These dissimilarities in absorbed radiation dose are due to developmental age variations (e.g., organ size, location, and overall metabolic rate for each age group). The identified critical organs (in descending order) across all age groups evaluated are the urinary bladder, heart, pancreas, spleen, and lungs.

Table 1. Estimated Absorbed Radiation Doses (rem/mCi) After Intravenous Administration of Fludeoxyglucose F18 Injection MIRDOSE 2 software was used to calculate the radiation absorbed dose. Assumptions on the biodistribution based on data from Gallagher et al.1 and Jones et al.2
Organ Newborn
(3.4 kg)
1-year old
(9.8 kg)
5-year old
(19 kg)
10-year old
(32 kg)
15-year old
(57 kg)
(70 kg)
Bladder wallThe dynamic bladder model with a uniform voiding frequency of 1.5 hours was used. 4.3 1.7 0.93 0.60 0.40 0.32
Heart wall 2.4 1.2 0.70 0.44 0.29 0.22
Pancreas 2.2 0.68 0.33 0.25 0.13 0.096
Spleen 2.2 0.84 0.46 0.29 0.19 0.14
Lungs 0.96 0.38 0.20 0.13 0.092 0.064
Kidneys 0.81 0.34 0.19 0.13 0.089 0.074
Ovaries 0.80 0.8 0.19 0.11 0.058 0.053
Uterus 0.79 0.35 0.19 0.12 0.076 0.062
LLI wallLLI = lower large intestine; 0.69 0.28 0.15 0.097 0.060 0.051
Liver 0.69 0.31 0.17 0.11 0.076 0.058
Gallbladder wall 0.69 0.26 0.14 0.093 0.059 0.049
Small intestine 0.68 0.29 0.15 0.096 0.060 0.047
ULI wallULI = upper large intestine 0.67 0.27 0.15 0.090 0.057 0.046
Stomach wall 0.65 0.27 0.14 0.089 0.057 0.047
Adrenals 0.65 0.28 0.15 0.095 0.061 0.048
Testes 0.64 0.27 0.14 0.085 0.052 0.041
Red marrow 0.62 0.26 0.14 0.089 0.057 0.047
Thymus 0.61 0.26 0.14 0.086 0.056 0.044
Thyroid 0.61 0.26 0.13 0.080 0.049 0.039
Muscle 0.58 0.25 0.13 0.078 0.049 0.039
Bone surface 0.57 0.24 0.12 0.079 0.052 0.041
Breast 0.54 0.22 0.11 0.068 0.043 0.034
Skin 0.49 0.20 0.10 0.060 0.037 0.030
Brain 0.29 0.13 0.09 0.078 0.072 0.070
Other tissues 0.59 0.25 0.13 0.083 0.052 0.042

Multiple-dose glass vial containing 0.74 - 11.1GBq (20 - 300 mCi/mL) of Fludeoxyglucose F18 Injection and 4.5 mg of sodium chloride in phosphate buffer per mL and ethanol (approximately 14 - 30 mL of total volume) for intravenous administration.


Radiation-emitting products, including Fludeoxyglucose F18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker[see Dosage and Administration(2.5)].

In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to Fludeoxyglucose F18 Injection administration.

Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting. Have emergency resuscitation equipment and personnel immediately available.

The possibility of interactions of Fludeoxyglucose F18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.

Pregnancy Category C

Animal reproduction studies have not been conducted with Fludeoxyglucose F18 Injection. It is also not known whether Fludeoxyglucose F18 Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Consider alternative diagnostic tests in a pregnant woman; administer Fludeoxyglucose F18 Injection only if clearly needed.

It is not known whether Fludeoxyglucose F18 Injection is excreted in human milk. Consider alternative diagnostic tests in women who are breast-feeding. Use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if Fludeoxyglucose F18 Injection is administered to a woman who is breast-feeding.

The safety and effectiveness of Fludeoxyglucose F18 Injection in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients. In pediatric patients with epilepsy, the recommended dose is 2.6 mCi. The optimal dose adjustment on the basis of body size or weight has not been determined. In the oncology or cardiology settings, the safety and effectiveness of Fludeoxyglucose F18 Injection have not been established in pediatric patients.

Fludeoxyglucose F18 Injection is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient 2-deoxy-2-[18F]fluoro-D-glucose has the molecular formula of C6H11 18FO5with a molecular weight oF181.26, and has the following chemical structure:

Fludeoxyglucose F18 Injection is provided as a ready to use sterile, pyrogen free, clear, colorless phosphate buffered solution. Each mL contains between 0.740 to 11.1GBq (20.0-300 mCi) of 2-deoxy-2-[18F]fluoro-D-glucose at the EOS, 4.5 mg of sodium chloride in phosphate buffer per mL and ethanol. The pH of the solution is between 4.5 and 7.5. The solution is packaged in a multiple-dose glass vial and does not contain any preservative.

Fluorine F18 decays by emitting positron to Oxygen O 16 (stable) and has a physical half-life of 109.7 minutes. The principal photons useful for imaging are the dual 511 keV gamma photons, that are produced and emitted simultaneously in opposite direction when the positron interacts with an electron (Table 2).

The specific gamma ray constant (point source air kerma coefficient) for fluorine F18 is 5.7 R/hr/mCi (1.35 x 10 -6 Gy/hr/kBq) at 1 cm. The half-value layer (HVL) for the 511 keV photons is 4 mm lead (Pb). The range of attenuation coefficients for this radionuclide as a function of lead shield thickness is shown in Table 3. For example, the interposition of an 8 mm thickness of Pb, with a coefficient of attenuation of 0.25, will decrease the external radiation by 75%.

For use in correcting for physical decay of this radionuclide, the fractions remaining at selected intervals after calibration are shown in Table 4.

Table 2. Principal Radiation Emission Data for Fluorine F18
Radiation/Emission % Per Disintegration Mean Energy
Positron(β+) 96.73 249.8 keV
Gamma(±)Produced by positron annihilation
From: Kocher, D.C. Radioactive Decay Tables DOE/TIC-I 1026, 89 (1981)
193.46 511.0 keV
Table 3. Radiation Attenuation of 511 keV Photons by lead (Pb) shielding
Shield thickness
(Pb) mm
Coefficient of
0 0.00
4 0.50
8 0.25
13 0.10
26 0.01
39 0.001
52 0.0001
Table 4. Physical Decay Chart for Fluorine F18
Minutes Fraction Remaining
0calibration time 1.000
15 0.909
30 0.826
60 0.683
110 0.500
220 0.250

Fludeoxyglucose F18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [18F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F18 reflect a balance involving glucose transporter, hexokinase and glucose-6-phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F18 transport and phosphorylation (expressed as the ''lumped constant'' ratio), Fludeoxyglucose F18 is used to assess glucose metabolism.

In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F18 reflect greater than normal rates of glucose metabolism.

Fludeoxyglucose F18 Injection is rapidly distributed to all organs of the body after intravenous administration. After background clearance of Fludeoxyglucose F18 Injection, optimal PET imaging is generally achieved between 30 to 40 minutes after administration.

In cancer, the cells are generally characterized by enhanced glucose metabolism partially due to (1) an increase in activity of glucose transporters, (2) an increased rate of phosphorylation activity, (3) a reduction of phosphatase activity or, (4) a dynamic alteration in the balance among all these processes. However, glucose metabolism of cancer as reflected by Fludeoxyglucose F18 accumulation shows considerable variability. Depending on tumor type, stage, and location, Fludeoxyglucose F18 accumulation may be increased, normal, or decreased. Also, inflammatory cells can have the same variability of uptake of Fludeoxyglucose F18.

In the heart, under normal aerobic conditions, the myocardium meets the bulk of its energy requirements by oxidizing free fatty acids. Most of the exogenous glucose taken up by the myocyte is converted into glycogen. However, under ischemic conditions, the oxidation of free fatty acids decreases, exogenous glucose becomes the preferred myocardial substrate, glycolysis is stimulated, and glucose taken up by the myocyte is metabolized immediately instead of being converted into glycogen. Under these conditions, phosphorylated Fludeoxyglucose F18 accumulates in the myocyte and can be detected with PET imaging.

In the brain, cells normally rely on aerobic metabolism. In epilepsy, the glucose metabolism varies. Generally, during a seizure, glucose metabolism increases. Interictally, the seizure focus tends to be hypometabolic.

Distribution: In four healthy male volunteers, receiving an intravenous administration of 30 seconds in duration, the arterial blood level profile for Fludeoxyglucose F18 decayed triexponentially. The effective half-life ranges of the three phases were 0.2-0.3 minutes, 10-13 minutes with a mean and standard deviation (STD) of 11.6 (±) 1.1 min, and 80-95 minutes with a mean and STD of 88 (±) 4 min.

Plasma protein binding of Fludeoxyglucose F18 has not been studied.

Metabolism:Fludeoxyglucose F18 is transported into cells and phosphorylated to [18F]-FDG-6- phosphate at a rate proportional to the rate of glucose utilization within that tissue. [F18]-FDG-6-phosphate presumably is metabolized to 2-deoxy-2-[F18]fluoro-6-phospho-D-mannose([F18]FDM-6-phosphate).

Fludeoxyglucose F18 Injection may contain several impurities (e.g., 2-deoxy-2-chloro-D-glucose (ClDG)). Biodistribution and metabolism of ClDG are presumed to be similar to Fludeoxyglucose F18 and would be expected to result in intracellular formation of 2-deoxy-2-chloro-6-phospho-D-glucose (ClDG-6-phosphate) and 2-deoxy-2-chloro-6-phospho-D-mannose (ClDM-6-phosphate). The phosphorylated deoxyglucose compounds are dephosphorylated and the resulting compounds (FDG, FDM, ClDG, and ClDM) presumably leave cells by passive diffusion. Fludeoxyglucose F18 and related compounds are cleared from non-cardiac tissues within 3 to 24 hours after administration. Clearance from the cardiac tissue may require more than 96 hours. Fludeoxyglucose F18 that is not involved in glucose metabolism in any tissue is then excreted in the urine.

Elimination:Fludeoxyglucose F18 is cleared from most tissues within 24 hours and can be eliminated from the body unchanged in the urine. Three elimination phases have been identified in the reviewed literature. Within 33 minutes, a mean of 3.9% of the administrated radioactive dose was measured in the urine. The amount of radiation exposure of the urinary bladder at two hours post-administration suggests that 20.6% (mean) of the radioactive dose was present in the bladder.

Special Populations: The pharmacokinetics of Fludeoxyglucose F18 Injection have not been studied in renally-impaired, hepatically impaired or pediatric patients. Fludeoxyglucose F18 is eliminated through the renal system. Avoid excessive radiation exposure to this organ system and adjacent tissues.

The effects of fasting, varying blood sugar levels, conditions of glucose intolerance, and diabetes mellitus on Fludeoxyglucose F18 distribution in humans have not been ascertained [see Warnings and Precautions(5.2)].

Animal studies have not been performed to evaluate the Fludeoxyglucose F18 Injection carcinogenic potential, mutagenic potential or effects on fertility.

The efficacy of Fludeoxyglucose F18 Injection in positron emission tomography cancer imaging was demonstrated in 16 independent studies. These studies prospectively evaluated the use of Fludeoxyglucose F18 in patients with suspected or known malignancies, including non-small cell lung cancer, colo-rectal, pancreatic, breast, thyroid, melanoma, Hodgkin's and non-Hodgkin's lymphoma, and various types of metastatic cancers to lung, liver, bone, and axillary nodes. All these studies had at least 50 patients and used pathology as a standard of truth. The Fludeoxyglucose F18 Injection doses in the studies ranged from 200 MBq to 740 MBq with a median and mean dose of 370 MBq.

In the studies, the diagnostic performance of Fludeoxyglucose F18 Injection varied with the type of cancer, size of cancer, and other clinical conditions. False negative and false positive scans were observed. Negative Fludeoxyglucose F18 Injection PET scans do not exclude the diagnosis of cancer. Positive Fludeoxyglucose F18 Injection PET scans can not replace pathology to establish a diagnosis of cancer. Non-malignant conditions such as fungal infections, inflammatory processes and benign tumors have patterns of increased glucose metabolism that may give rise to false-positive scans. The efficacy of Fludeoxyglucose F18 Injection PET imaging in cancer screening was not studied.

The efficacy of Fludeoxyglucose F18 Injection for cardiac use was demonstrated in ten independent, prospective studies of patients with coronary artery disease and chronic left ventricular systolic dysfunction who were scheduled to undergo coronary revascularization. Before revascularization, patients underwent PET imaging with Fludeoxyglucose F18 Injection (74 – 370 MBq, 2 – 10 mCi) and perfusion imaging with other diagnostic radiopharmaceuticals. Doses of Fludeoxyglucose F18 Injection ranged from 74-370 MBq (2-10 mCi). Segmental, left ventricular, wall-motion assessments of asynergic areas made before revascularization were compared in a blinded manner to assessments made after successful revascularization to identify myocardial segments with functional recovery.

Left ventricular myocardial segments were predicted to have reversible loss of systolic function if they showed Fludeoxyglucose F18 accumulation and reduced perfusion (i.e., flow-metabolism mismatch). Conversely, myocardial segments were predicted to have irreversible loss of systolic function if they showed reductions in both Fludeoxyglucose F18 accumulation and perfusion (i.e., matched defects).

Findings of flow-metabolism mismatch in a myocardial segment may suggest that successful revascularization will restore myocardial function in that segment. However, false-positive tests occur regularly, and the decision to have a patient undergo revascularization should not be based on PET findings alone. Similarly, findings of a matched defect in a myocardial segment may suggest that myocardial function will not recover in that segment, even if it is successfully revascularized. However, false-negative tests occur regularly, and the decision to recommend against coronary revascularization, or to recommend a cardiac transplant, should not be based on PET findings alone. The reversibility of segmental dysfunction as predicted with Fludeoxyglucose F18 PET imaging depends on successful coronary revascularization. Therefore, in patients with a low likelihood of successful revascularization, the diagnostic usefulness of PET imaging with Fludeoxyglucose F18 Injection is more limited.

In a prospective, open label trial, Fludeoxyglucose F18 Injection was evaluated in 86 patients with epilepsy. Each patient received a dose of Fludeoxyglucose F18 Injection in the range oF185-370 MBq (5-10 mCi). The mean age was 16.4 years (range: 4 months - 58 years; of these, 42 patients were less than 12 years and 16 patients were less than 2 years old). Patients had a known diagnosis of complex partial epilepsy and were under evaluation for surgical treatment of their seizure disorder. Seizure foci had been previously identified on ictal EEGs and sphenoidal EEGs. Fludeoxyglucose F18 Injection PET imaging confirmed previous diagnostic findings in 16% (14/87) of the patients; in 34% (30/87) of the patients, Fludeoxyglucose F18 Injection PET images provided new findings. In 32% (27/87), imaging with Fludeoxyglucose F18 Injection was inconclusive. The impact of these imaging findings on clinical outcomes is not known.

Several other studies comparing imaging with Fludeoxyglucose F18 Injection results to subsphenoidal EEG, MRI and/or surgical findings supported the concept that the degree of hypometabolism corresponds to areas of confirmed epileptogenic foci. The safety and effectiveness of Fludeoxyglucose F18 Injection to distinguish idiopathic epileptogenic foci from tumors or other brain lesions that may cause seizures have not been established.

Fludeoxyglucose F18 Injection is supplied in a multi-dose, capped 30 mL glass vial containing between 0.740 – 11.1GBq/mL (20 - 300 mCi/mL), of no carrier added 2-deoxy-2-[F18] fluoro-D-glucose, at end of synthesis, in approximately 14 - 30 mL. The contents of each vial are sterile, pyrogen-free and preservative-free.

NDC 24562-003-30

This radiopharmaceutical is licensed by the State of Louisiana Department of Environmental Quality Office of Environmental Compliance, Radiation Licensing Division for distribution to persons licensed pursuant to Louisiana's Environmental Regulatory Code, Part XV: Radiation Protection, as appropriate, or under equivalent licenses of an Agreement State or Licensing State.

Store the Fludeoxyglucose F18 Injection vial upright in a lead shielded container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).

Store and dispose of Fludeoxyglucose F18 Injection in accordance with the regulations and a general license, or its equivalent, of an Agreement State or a Licensing State.

The expiration date and time are provided on the container label. Use Fludeoxyglucose F18 Injection within 12 hours from the EOS time.

Instruct patients in procedures that increase renal clearance of radioactivity. Encourage patients to:

Manufactured for:Biomedical Research Foundation of Northwest LouisianaShreveport, LA 71103

Revised: May 2015



Multiple-Dose Vial

Fludeoxyglucose F 18 Injection 20 – 300 mCi/mL (@ EOS*)

Sterile, Non-pyrogenic                Date _________                Exp. _________

Diagnostic – For Intravenous Use OnlyLot#____________________(Expires 12 hours after EOS*)

Contains: 0.74-11.1 GBq (20-300mCi) of no-carrier added Fludeoxyglucose F 18 (2-deoxy-2-[F]fluoro-D-glucose) @ EOS*and 4.5 mg of sodium chloride in phosphate buffer per mL and ethanol.

Store at 25°C (77°F) (see insert)Store upright in a shielded container.Aseptically withdraw and handle doses.

[F] Half-Life = 109.7 minutesCalculate correct dosage from date andtime of calibration.

Do not use if cloudy or if it contains particulate matter.*EOS = End of Synthesis


Manufactured for:Biomedical Research Foundation of NorthwestLouisianaShreveport, LA 71103



Biomedical Research Foundation of Northwest Louisiana

Active Ingredients


Drugs and Medications [36 Associated Drugs and Medications listed on BioPortfolio]

Fludeoxyglucose f18 [the methodist hospital research institute]

Fludeoxyglucose F18 Injection USP - NO CHANGE

Fludeoxyglucose [houston cyclotron partners lp dba cyclotope]

These highlights do not include all the information needed to use Fludeoxyglucose F18 Injection safely and effectively. See full prescribing information for Fludeoxyglucose F18 Injection. Fludeoxygluc...

Fludeoxyglucose [the university of texas md anderson cancer center]

These highlights do not include all the information needed to use Fludeoxyglucose F18 Injection safely and effectively. See full prescribing information for Fludeoxyglucose F18 Injection. Fludeoxygluc...

Fludeoxyglucose f 18 [hamamatsu/queen’s pet imaging center, llc]

Fludeoxyglucose F 18 Injection, USP, For Intravenous Use

Fludeoxyglucose f18 [the feinstein institute for medical research]

These highlights do not include all the information needed to use Fludeoxyglucose F18 Injection safely and effectively. See full prescribing information for Fludeoxyglucose F18 Injection. Fludeoxygluc...

Clinical Trials [98 Associated Clinical Trials listed on BioPortfolio]

Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules

RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before and after steroid therapy may help doctors assess a patient's response to treatment and help plan...

Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors

RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 PET/CT scan done before and during surgery, may help doctors find tumor cells during surgery. These scans may also help the doct...

Fludeoxyglucose F 18 PET Scans in Predicting Outcomes in Patients Who Have Undergone High-Dose Chemotherapy and Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma

RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 PET scans, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase ...

Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein

RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 positron emission tomography, may help find and diagnose cancer. It is not yet known whether standard diagnostic procedures a...

Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery

RATIONALE: Diagnostic procedures using fludeoxyglucose F 18 and a surgical probe may help find lymph node metastases in patients with early-stage non-small cell lung cancer. PURPOSE: This...

PubMed Articles [5 Associated PubMed Articles listed on BioPortfolio]

Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence.

No guidelines at present describe when fludeoxyglucose F 18-labeled positron emission tomography and computed tomography (FDG PET-CT) should be used in the initial posttreatment period for evaluation ...

Quantitative analysis of image metrics for reduced and standard dose pediatric F-FDG PET/MRI examinations.

The study performs a comprehensive analysis of image metrics to objectively support the reduction of injected activity in pediatric oncology F-FDG PET/MR (F-fludeoxyglucose PET/MR) examinations. Contr...

Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies.

Primary bone malignancies are characterized with anatomic imaging. However, in recent years, there has been an increased interest in PET/computed tomography scanning and PET/MRI with fludeoxyglucose F...

Association Between Aortic Vascular Inflammation and Coronary Artery Plaque Characteristics in Psoriasis.

Inflammation is critical to atherosclerosis. Psoriasis, a chronic inflammatory disease associated with early cardiovascular events and increased aortic vascular inflammation (VI), provides a model to ...

Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.

Pancreatic cancer is the 4th most common cause of cancer death in Japan and exhibits a 5-year overall survival rate of approximately 7%. The accurate diagnosis of pancreatic cancer is important for de...

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record